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INTRODUCTION 
 Central neuraxial blockade is one of the most commonly performed 
technique in modern anaesthesia. In 1898, August Bier first described 
"cocainisation of the spinal cord". Over the years, the technique has been 
refined and has evolved into the modern concept of  intrathecal, spinal or 
subarachnoid block. Spinal effects are produced by slow injection of a 
small volume of local anaesthetic solution containing dextrose (to make it 
hyperbaric). 
 Among the regional techniques available, spinal anaesthesia is an 
attractive option when the surgical site is below umbilicus
[1]
. It produces 
dense sensory, motor and sympathetic blockade. It has the advantages of 
low cost, better postoperative pain relief, decreased PONV, low incidence 
of thromboembolism  when compared to general anaesthesia. 
Subarachnoid block is associated with reduced stage I recovery time and 
patients can resume their normal oral intake quickly. Because of these 
benefits, spinal anaesthesia is one of the emerging technique in day care 
surgeries in recent times. 
 Spinal anaesthesia is beneficial in terms of decreasing 
intraoperative blood loss, blunting the stress response to surgery and 
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reducing mortality and morbidity in high risk surgical patients. 
Subarachnoid block is a preferred technique in patients who are prone to 
aspiration like obesity, full stomach, GERD and in patients with reduced 
respiratory drive. 
   In spite of the above benefits, the major limitation of subarachnoid 
block is short lived duration of anaesthesia. Normally, spinal anaesthesia 
with bupivacaine heavy (H) lasts for 2 to 2.5 hours
[2]
. Addition of 
adjuvants like opioids, neostigmine and epinephrine to the local 
anaesthetics intrathecally, results in prolongation of duration of 
anaesthesia. 
 In 1979, Wang and his colleagues
[3]
 first used intrathecal opioids 
for acute pain treatment. Intrathecal opioid is widely used in treating 
intraoperative, postoperative, obstetric, traumatic and chronic cancer 
pain. The technique of intrathecal opioid administration along with local 
anaesthetics is to improve the quality of analgesia and decrease the 
requirement of postoperative analgesics
[4]
. 
 The basis for the combination of local anesthetics and opioids is 
that these two groups of drugs provide analgesia by their action at two 
different sites. Local anesthetics have their action at the spinal nerve axon 
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and opioids act at the receptor site in the spinal cord
[5]
. Various opioids 
have been used intrathecally like morphine, fentanyl, buprenorphine and 
nalbuphine to fasten the onset and prolong the duration of sensory and 
motor blockade. 
 Nalbuphine is an opioid, synthetically prepared with mixed µ 
antagonist and κ agonist properties[6]. Nalbuphine when administered 
intrathecally binds to kappa receptors in the spinal cord and brain  
producing analgesia and sedation without µ adverse effects. It has 
minimal respiratory depressant effect and low abuse potential compared 
to other centrally acting opioid analgesics. Side effects like shivering, 
nausea, vomiting and urinary retention are infrequent with nalbuphine 
hydrochloride. Increased drug dosage is not required, Since nalbuphine 
reaches ceiling effect at lower intrathecal dosage. This also explains the 
safety margin of the drug. 
 In this study, we investigated the addition of nalbuphine 
hydrochloride as an adjuvant to hyperbaric bupivacaine in subarachnoid 
block, in comparison with hyperbaric bupivacaine alone in order to 
evaluate the beneficial effects of nalbuphine. 
  
Aim of the
study
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AIM OF THE STUDY 
 The aim of the study was to compare the anaesthetic efficacy of 
mixture of intrathecal bupivacaine 0.5% heavy and nalbuphine 
hydrochloride with intrathecal bupivacaine 0.5% heavy alone for 
infraumbilical surgeries. 
  
 
 
 
 
 
 
Objectives
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OBJECTIVES 
The objective of the study was to compare the 
1. Onset of sensory and motor blockade  
2. Duration of sensory, motor blockade and postoperative analgesia 
between the two groups of patients who had undergone 
infraumblical surgeries under spinal anaesthesia using bupivacaine 
heavy with or without nalbuphine. 
 
 
 
Review
Of
Literature
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REVIEW OF LITERATURE 
 Khosrou Naghibi, Hamid Saryazdi, Farnaz Rohani
[7]
 et al 
conducted a study in 2013 titled "The comparison of spinal anesthesia 
with general anesthesia on the postoperative pain scores and analgesic 
requirements after elective lower abdominal surgery". It was a 
prospective randomized controlled double blinded study. After obtaining 
informed written consent, sixty eight patients under American Society of 
Anaesthesiologist physical status I and II in the age group of 20-65 
planned for elective lower abdominal surgery under general anaesthesia 
or spinal anaesthesia were included in the study. Patients were randomly 
divided into GA or SA by using sealed envelopes with thirty four patients 
in each group. VAS score was explained to all the patients prior to 
surgery. On arrival to the operating room, basic monitors 
[Electrocardiography, Noninvasive blood pressure, Pulse oximetry] were 
connected and IV line started with 18G cannula. 
 Group SA - received 3ml of 0.5% hyperbaric bupivacaine (15mg) 
intrathecally, at L3-L4 interspace and 2μ/kg fentanyl intravenously 
for intraoperative analgesia. 
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 Group GA - received Na thiopental 6mg/kg, fentanyl 2 μ/kg, 
morphine 0.15mg/kg, atracurium 0.6mg/kg for induction followed 
by tracheal intubation. Maintenance with O2/N20/isoflurane. 
Reversal with 0.02mg/kg atropine and 0.04 mg/kg neostigmine. 
The pain scores and the analgesic requirements were noted in the 
recovery room for 24 hours after surgery. The authors concluded that the 
patients in SA group had comparatively lower VAS scores than the 
patients in GA group for the first 6 hours (3.4±1.6 and 4.1±1.2 vs 5.2±1.5 
and 5.8±0.9 at 2nd and 4th hour postoperatively). Postoperative analgesic 
requirements was also significantly (p<0.05) reduced in SA group. 
However there was no significant difference between the two groups after 
6 hours. 
 Mukherjee A, Pal A, Agrawal J
[8]
 et al did a study in 2011 titled 
"Intrathecal nalbuphine as an adjuvant to subarachnoid block: What is the 
most effective dose?". It was a randomized, prospective double blind 
controlled study. Hundred  patients of ASA physical status I and II  
posted for elective lower limb orthopedic surgery under subarachnoid 
block were included in the study .They were allotted into four groups A, 
B,C and D by computer generated randomisation. 
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 Group A - received 0.5ml Normal Saline with 12.5mg bupivacaine 
0.5% (H) 
 Group B - received 0.2mg Nalbuphine with  12.5mg bupivacaine 
0.5% (H) 
 Group C - received 0.4mg Nalbuphine with  12.5mg bupivacaine 
0.5% (H) 
 Group D - received 0.8mg Nalbuphine with  12.5mg bupivacaine 
0.5% (H). 
 Haemodynamic parameters like heart rate, mean arterial 
pressure(MAP) & peripheral oxygen saturation were noted throughout the 
procedure. They compared the onset of sensory and motor blockade and 
duration of sensory and motor blockade between the groups. They used 
Bromage scale for motor block and visual analogue scale for assessing 
pain. The onset time of sensory and motor blockade was significantly 
(p<0.05 ) reduced and the duration of block was increased in nalbuphine 
groups. They observed that the analgesic effect of bupivacaine was 
significantly prolonged when nalbuphine was added as an adjuvant. The 
authors concluded that 0.4mg Nalbuphine is the most effective intrathecal 
dose that prolongs post operative analgesia with no side-effects. 
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 Jyothi B, Shruthi Gowda, Safiya Shaikh
[9]
 conducted a study in 
2014 titled "A comparison of analgesic effect of different doses of 
intrathecal nalbuphine hydrochloride with bupivacaine and bupivacaine 
alone for lower abdominal and orthopedic surgeries". Hundred patients of  
both sexes under American Society of Anaesthesiologists I and II were 
enrolled in the study. They were randomly allocated into four groups 
I,II,III,IV. It was a double blind randomized controlled study. Prior to 
SAB, monitors like ECG, pulse oximetry, non invasive blood pressure 
(NIBP) were connected and base line values were recorded. Patients were 
preloaded with 500ml of RL solution. Subarachnoid block was performed 
using 25G Quincke needle in L3-L4 interspace with 15mg bupivacaine + 
0.5ml NS(Group I) or 15mg of bupivacaine with either of nalbuphine 
0.8mg, 1.6 and 2.5mg (Group II,III and IV). The time to two segment 
regression of sensory blockade and the duration of analgesia was 
significantly prolonged in nalbuphine groups. The postoperative pain 
scores were drastically reduced in group II to IV than group I (3.4±0.4 vs 
4.08±0.5). The authors concluded addition of 0.8mg nalbuphine to 
bupivacaine 0.5% intrathecally provides excellent analgesia without any 
side effects. Nalbuphine exhibits analgesic ceiling effect at 0.8mg dosage, 
further increase in dose did not rise the analgesic efficacy. 
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 Shehla shakooh, Pooja Bhosle
[10]
 performed a study titled 
"Intrathecal nalbuphine: An effective adjuvant for post operative 
analgesia". It was a prospective randomised double blind study. After 
approval by the ethics committee, 60 patients under ASA PS I and II 
posted for elective lower abdominal and lower limb surgery were 
included in the study. Patients were divided into two groups by slips in 
the box technique. Group N received 0.5% heavy bupivacaine (3cc) with 
0.8mg nalbuphine. Group B received 0.5% heavy bupivacaine (3cc). 
Intraoperatively basic monitors were connected and subarachnoid block 
was performed by 25G Quincke needle in right lateral position. 
Hemodynamic parameters were observed throughout the procedure. 
Sensory and motor block were assessed by pinprick and Bromage scale 
respectively. The authors concluded that the onset of sensory and motor 
blockade were faster in group N with a significant p value (0.001). The 
duration of sensory & motor block and the postoperative analgesia 
duration were superior in group N as compared to group B. No significant 
side effects were reported between the two groups. 
 Mostafa Galal, Mohamad F
[11]
 et al performed a study in 2011 
regarding "Which has greater analgesic effect: Intrathecal Nalbuphine or 
Intrathecal Tramadol?".  Sixty patients posted for Transurethral resection 
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of the bladder tumor (TURBT) under the ASA physical status I and II 
were enrolled in the study. They were randomly divided into two groups 
 Group T - received 15mg of  0.5% hyperbaric bupivacaine plus 
50mg of tramadol hydrochloride preservative free ( Total volume = 
4ml). 
 Group N - received 15mg of  0.5% hyperbaric bupivacaine plus 
2mg of nalbuphine hydrochloride preservative free (Total volume 
= 4ml). 
Spinal block was performed with 25G Quincke's needle in L3-L4 
space with the patient in right lateral decubitus position. They studied 
postoperative analgesic requirements, sedation scores, Visual Analog 
Scale for pain intensity and side effects. The authors concluded that 
intrathecal tramadol and nalbuphine when used with bupivacaine 0.5% 
produce similar postoperative analgesia, however sedation scores were 
higher in tramadol group. 
 Lin M L
[12]
 conducted a study in 1992 regarding "The analgesic 
effect of subarachnoid administration of tetracaine combined with low 
dose of morphine or nalbuphine for spinal anaesthesia". Sixty adult 
patients under the American Society of Anaesthesiologists (ASA) I and II 
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posted for lower limb surgeries were included in the study. Patients were 
randomized into two groups using computer generated random numbers. 
One group received 0.4mg morphine with tetracaine and another group 
received 0.4mg nalbuphine with tetracaine. Prior to spinal anaesthesia 
monitors like ECG, pulse oximetry for SPO2 and non invasive blood 
pressure were connected. Patients were preloaded with 500ml of Ringer 
Lactate solution. Spinal block was done with 26gauge Quincke's needle at 
L3-L4 interspace in sitting posture. Sensory level, motor block, VAS 
score were recorded serially. They found that addition of nalbuphine or 
morphine to hyperbaric tetracaine for SAB significantly decreases the 
onset time of sensory block, prolongs the duration of sensory and motor 
blockade and the time for first postoperative analgesic requirement. Side 
effects were less in  nalbuphine group than in morphine group. 
 Ravikiran J Thote, Prashant Lomate, Shilpa Gaikwad
[13]
 et al 
performed a study in 2015 titled " Comparison among intrathecal fentanyl 
and nalbuphine in combination with bupivacaine and plain bupivacaine 
for lower limb surgeries". The study design was a prospective randomised 
controlled double blind study. Sixty patients of  both sexes posted for 
lower limb surgeries under ASA PS I and II were enrolled in the study. 
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They were segregated into three groups of 20 patients each using 
computer generated random numbers. 
 Group I - received 2.5ml of 0.5% bupivacaine plus 0.5ml of 25mcg 
of fentanyl. 
 Group II - received 2.5ml of 0.5% bupivacaine plus 0.5ml of 
500mcg nalbuphine. 
 Group III - received 2.5ml of 0.5% bupivacaine plus 0.5ml of 
normal saline.  
Basic monitors of blood pressure, heart rate and oxygen saturation 
(SPO2) were connected. Intravenous lines started with an 18G cannula 
and RL infusion was started. SAB was performed with 25G gauge pencil 
point needle at L3-L4 interspace. The onset of sensory and motor 
blockade were significantly shorter in fentanyl and nalbuphine group. 
However the duration of sensory block was increased with nalbuphine- 
bupivacaine combination than fentanyl bupivacaine combination. 
Arousable sedation without any respiratory depression was noted with 
nalbuphine. 
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 Xavier Culebras, Giovanni Gaggero
[14]
 et al performed a study in 
2000 titled "Advantages of  Intrathecal Nalbuphine, Compared with 
Intrathecal Morphine, After Cesarean Delivery:An Evaluation of 
Postoperative Analgesia and Adverse Effects". After the approval from 
ethical committee and getting informed consent, ninety healthy 
parturients at term for elective cesarean delivery under spinal anaesthesia 
were included in the study. It was a randomized, prospective double 
blinded study. Patients received 10mg of  0.5% heavy bupivacaine with 
either morphine 0.2mg (category A), nalbuphine 0.2mg (category B), 
nalbuphine 0.8mg (category c), nalbuphine 1.6mg (category D). They 
found that postoperative analgesia was significantly longer in the 
morphine category than nalbuphine (P < 0.0001). Among the nalbuphine 
categories, postoperative analgesia was longer with 0.8mg. Adverse 
effects like pruritus, nausea and vomiting were frequently encountered 
with morphine when compared to nalbuphine. APGAR scores were 
similar in all groups. There was no newborn or maternal respiratory 
depression. The authors had concluded that 0.8mg intrathecal nalbuphine 
provides good intraoperative analgesia and improves postoperative 
analgesia without adverse effects.  
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 Fournier R, Van Gessel E, Macksay M, Gamulin Z
[15]
  performed a 
study in 1998 regarding "The onset and offset of  intrathecal morphine 
versus nalbuphine for postoperative pain relief after total hip 
replacement". The objective of the study was to compare the 
postoperative analgesia caused by intrathecal morphine and nalbuphine. 
After the approval from ethical committee, twenty four geriatric patients 
posted for elective total hip replacement (THR) under continuous spinal 
anesthesia were randomized into two double blinded groups. Spinal block 
was performed by 25G quincke needle in L3-L4 space with 3.5ml of 
0.5% bupivacaine heavy.  In the recovery room, when they experienced 
pain (VAS > 3), either 160μgram morphine or 400μgram nalbuphine 
(diluted in 4ml NS) were given intrathecally. Patients were followed up 
for the next 24 hours after surgery. The authors found that intrathecal 
nalbuphine produces faster onset of pain relief but shorter duration of 
analgesia than morphine.    
 Moustafa AA, Baaror AS, Abdelazim IA
[16]
 et al performed a study 
titled "Comparative study between nalbuphine and ondansetron in 
prevention of intrathecal morphine -induced pruritus in women 
undergoing cesarean section". After approval from the Institute Ethical 
committee and after informed written consent, ninety pregnant women of 
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ASA physical status II scheduled for cesarean delivery under spinal 
anaesthesia were recruited for this study. They were divided into three 
groups. SAB performed in left lateral position at L3-4 interspace using 
25G Quincke spinal needle with 2.2ml of 0.5% (H) bupivacaine and 0.2 
mg morphine. Immediately after delivery of baby they received one of the 
following  
 Placebo group (P) - received 4ml of normal saline(NS) IV 
injection. 
 Nalbuphine group (N) - received 4ml of 4mg nalbuphine IV. 
 Ondansetron group (O) - received 4ml of 4mg ondansetron IV. 
Patients were observed  for pruritus scores, blood pressure, heart 
rate and SPO2 in the post anaesthesia care unit (PACU) for four hours. 
Both nalbuphine and ondansetron were effective for prevention of 
intrathecal morphine induced pruritus in parturients undergoing cesarean 
delivery. However nalbuphine was preferred because it is not excreted in 
breast milk. 
 Chatrath V, Attri
[17]
 et al conducted a study regarding  "The effect 
of  epidural nalbuphine for postoperative analgesia in orthopedic 
surgery". A double blind prospective randomised study was performed 
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with eighty adult patients of American Society of Anaesthesiologists 
(ASA) I and II category posted for elective lower limb orthopedic 
surgeries under combined spinal epidural anaesthesia. Patients were 
divided into two categories using computer randomisation method. 
 Group A - received epidurally 10ml of 0.25% bupivacaine along 
with 10mg nalbuphine. 
 Group B - received epidurally 10ml of  0.25% bupivacaine along 
with 100mg tramadol. 
  Baseline hemodynamic parameters like heart rate, mean arterial 
blood pressure and oxygen saturation were noted. Subarachnoid block 
was given with 0.5% of 2.5ml bupivacaine in both the groups. Epidural 
top up was given at sensory regression to T10. Mean duration of 
analgesia and mean sedation score were compared between the groups. 
They concluded that the quality of analgesia and patient satisfaction score 
were better with nalbuphine epidurally than with tramadol. 
 Ananda Bangera, Krishna Prasad
[18]
 et al conducted a study titled 
"Nalbuphine as an alternate analgesic to morphine in total abdominal 
hysterectomy". After approval from Institutional ethics committee (IEC) 
and obtaining informed consent, fifty patients under the ASA PS I and II 
  
18 
scheduled for total abdominal hysterectomy (TAH) were included in the 
study. Visual Analog Scale for pain assessment was explained to the 
patients prior to surgery. Patients were allocated randomly into two 
groups by closed envelope method. Injection diazepam 0.1mg/kg was 
given 30 minutes prior to induction of anaesthesia. General anaesthesia 
was standardised in both the groups. After preoxygenation    
 Group N received 0.2mg/kg nalbuphine IV  
 Group M received 0.1mg/kg morphine IV 
Both groups were induced with propofol 2mg/kg and paralysed 
with vecuronium bromide 0.1mg/kg, followed by tracheal intubation. 
Anaesthesia was maintained with O2/N2O/isoflurane. At the end of 
surgical procedure, patients were reversed with neostigmine 50mcg/kg 
and glycopyrrolate 10mcg/kg and extubated. Intraoperative 
hemodynamics and duration of post operative analgesia were noted. 
Duration of analgesia was significantly more in nalbuphine patients than 
morphine patients (437±63.87 min vs 255±43.75min). The time to first 
analgesic requirement was significantly longer with intravenous 
nalbuphine in addition to better intraoperative hemodynamic stability. 
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 Mohamed Abdelhaq, Mohamed Adly
[19]
 conducted a study 
regarding the "Effect of nalbuphine as adjuvant to bupivacaine for 
ultrasound-guided supraclavicular brachial plexus block". It was a 
randomised double blind control study.  VAS score was explained to all 
candidates where 0 corresponds to no pain and 10 is indicative of worst 
unbearable pain. After obtaining ethical committee approval, 56 patients 
posted for forearm and hand surgeries in the age group of 18-60 years 
under the ASA physical status I and II were enrolled in the study. Patients 
were randomly allocated into two equal study groups. 
 Group C - received 25 ml of 0.5% bupivacaine and 1 ml normal 
saline 
 Group N - received 25 ml of 0.5% bupivacaine and 1 ml 
nalbuphine (20mg ). 
On arrival to the operating room, IV line started with an 20G 
intravenous cannula and Ringer lactate infusion was started. Baseline 
values of blood pressure, heart rate and haemoglobin oxygen saturation 
were recorded. The supraclavicular block was performed with the ultra 
sound system. The authors concluded that addition of nalbuphine to 
bupivacaine in supraclavicular block is associated with increase in 
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duration of both sensory and motor block and duration of postoperative 
analgesia (835.18±42.45 min vs 708.14±54.57). 
 Maha M.I. Youssef, Nashwa S. EiZayyat
[20]
 performed a study in 
2014 titled "Lidocaine-nalbuphine Versus lidocaine-tramadol for 
intravenous regional anesthesia". After approval from local ethics 
committee and taking informed consent, sixty patients in the age group of 
20 - 60 years under the American Society of Anaesthesiologists physical 
status I and II scheduled for minor hand surgeries were included in the 
study. The pain score was assessed by 10 point verbal rating scale. By 
random allocation patients were divided into three equal groups using 
computer based lists. Group L received 3mg/kg lidocaine 0.5% diluted in 
40 ml isotonic saline. Group LT received 3mg/kg lidocaine 0.5% and 
100mg tramadol diluted in 40 ml isotonic saline. Group LN received 
3mg/kg lidocaine 0.5% and 10mg nalbuphine diluted in 40 ml isotonic 
saline. In the operating room, patients were monitored by ECG, NIBP and 
SPO2. Intravenous regional anesthesia was performed by using double 
pneumatic tourniquet and Esmarch elastic bandage in all patients. The 
parameters like latency time, duration of sensory and motor block and 
duration of analgesia were noted. The use of nalbuphine and tramadol as 
adjuvants accelerate the onset and prolongs the duration of both sensory 
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and motor block. Nalbuphine seems to be superior to tramadol in 
prolonging the duration of postop analgesia. 
 Lefevre B, Freysz M
[21]
 et al conducted a study  in 1992 titled 
"Comparison of nalbuphine and fentanyl as intravenous analgesics for 
medically compromised patients undergoing oral surgery". Twenty four 
patients of both sexes scheduled for oral surgery under the ASA physical 
status III or IV were included in the study. They had been double blindly 
randomized into two groups. Upon arrival to the operating room IV line 
was started with 18G Quincke needle and RL infusion started. One group 
received IV analgesia with 0.2mg/kg nalbuphine  and another group 
received  IV analgesia with 2mcg/kg fentanyl. Three minutes later local 
anaesthesia was administered in both the groups.  Respiratory rate, 
oxyhemoglobin saturation (SpO2), heart rate and arterial blood pressure 
were recorded before and during surgery. The parameters like quality of 
analgesia, sedation scores, respiratory depression were noted. The authors 
concluded that there was no significant differences regarding analgesia 
and sedation between the two drugs. They also empathised that 
nalbuphine produce less respiratory depression and it should be a suitable 
alternative to fentanyl in medically compromised patients undergoing oral 
surgery. 
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 Hala Mostafa Gomaa, Nashwa nabil Mohamed
[22]
 et al conducted a 
study in 2013 titled "A comparison between post-operative analgesia after 
intrathecal nalbuphine with bupivacaine and intrathecal fentanyl with 
bupivacaine after cesarean section". Sixty pregnant females posted for 
elective LSCS under the ASA physical status II were included in the 
study. The patients after obtaining informed consent were divided into 
two groups. Group F received 2ml of 0.5% hyperbaric bupivacaine plus 
0.5ml fentanyl(25µg) intrathecally. Group N received 2ml of 0.5% 
hyperbaric bupivacaine plus 0.5ml nalbuphine hydrochloride(0.8mg) 
intrathecally. The time to reach the T10 sensory segment was not 
significantly different between the two groups. However, the duration of  
intraoperative analgesia and early postoperative analgesia  was prolonged 
in group N compared to group F.  
 Pallavi Ahluwalia, Amit Ahluwalia
[23]
 et al conducted a study in 
2015 titled "A prospective randomized double-blind study to evaluate the 
effects of intrathecal nalbuphine in patients of lower abdominal surgeries 
under spinal anaesthesia". After obtaining informed consent, seventy 
adult patients of both sexes aged between 18-60 years under ASA PS I 
and II posted for lower abdominal surgeries were included in the study. 
They were randomly divided into two groups. Group N received 2.5ml of 
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0.5% bupivacaine + nalbuphine 0.8mg (made upto 0.5ml) intrathecally. 
Group C received 2.5ml of 0.5% bupivacaine + normal saline (0.5ml) 
intrathecally. Prior to spinal anaesthesia monitors like NIBP, pulse 
oximetry, ECG were connected and the patients were hydrated with RL at 
10ml/kg. Intradural puncture was performed at L3-L4 space with 25G 
Quincke needle in lateral decubitus position. They concluded that the 
addition of nalbuphine as adjuvant to bupivacaine intrathecally fastens 
the onset of sensory blockade (1.29±0.43min vs 3.78±1.31min) and 
prolongs the duration of sensory and motor blockade. The time to first 
analgesic requirement was longer in group N as compared to group C 
(298.43±30.92min vs 201.31±34.31min). 
 Priti M Chawda, Mayuresh K Pareek
[24]
 et al did a study titled 
"Effect of nalbuphine on haemodynamic response to orotracheal 
intubation". After obtaining ethics committee(IEC) approval, sixty 
patients of both sexes under ASA grade I and II scheduled for laproscopic 
surgery were included in the study. Patients were divided into two equal 
groups. All the patients were premedicated with glycopyrrolate 4μg/kg  
and midazolam 1 mg 10 mins prior to induction of anaesthesia. Patients 
were monitored for ECG, MAP, SPO2 and capnography. Group I 
received 5ml normal saline (NS)and Group II received 5ml of 0.2mg/kg 
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nalbuphine five minutes before induction. Preoxygenation followed by 
induction with thiopentone 5mg/kg, Scoline 1.5mg/kg and orotracheal 
intubation was performed within 30 secs. HR and MAP were measured 
just after intubation and every 1 minute upto 10 mins. Anaesthesia 
maintained with O2/N20/sevoflurane. Reversal with 0.02mg/kg atropine 
and 0.04 mg/kg neostigmine and the patients were extubated. Pressor 
response were compared between the two groups before and after 
intubation. They concluded that nalbuphine prevented a marked rise in 
heart rate(HR) and mean arterial pressure(MAP) associated with 
laryngoscopy and tracheal intubation. 
 Chandrakar N, Lalwani J, Sahare KK
[25]
 et al conducted a study 
regarding "The use of patient controlled analgesia using I.V tramadol and 
I.V nalbuphine for postoperative pain management after major abdominal 
surgery".  The study was a prospective randomised controlled double 
blind trial. Eighty patients of ASA I and II were selected after approval 
from ethics committee and obtaining informed consent. 40 patients were 
allocated in each group. During the preoperative assessment, use of 
Patient Controlled Analgesia (PCA) for postoperative pain relief  and 
VAS scale was explained. Injection glycopyrrolate 0.004 mg/kg, 
midazolam 0.05 mg/kg  were given as premedicants. General anesthesia 
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was standardised in both groups. Pentazocine 0.5 mg/kg, thiopental 5 
mg/kg and atracurium 0.5mg/kg were given for tracheal intubation. 
Anaesthesia  was maintained with O2/N2O/isoflurane. Reversal was done 
with neostigmine 50mcg/kg and glycopyrrolate 10mcg/kg. PCA was 
started in the immediate postoperative period. 
 Group T - received IV tramadol ( 10 mg bolus dose in 
concentration of 5mg/ml, lockout interval 10 min) 
 Group N - received IV nalbuphine (2 mg bolus dose, lock out 
interval 10 min) 
VAS scale and sedation score were assessed for 24 hours. The 
authors concluded that Visual Analog Scale was significantly reduced in 
nalbuphine group compared to tramadol. They also found that nalbuphine 
provides better hemodynamic stability, good sedation and significantly 
lower incidence of nausea and vomiting. 
 RH Saleh, MF Yousef
[26]
 et al conducted a study regarding "The 
effect of nalbuphine as an adjuvant on levobupivacaine induced caudal 
analgesia in children undergoing surgical procedures". 40 patients aged 1-
9 years scheduled for pelvi-abdominal surgeries under ASA PS I and II 
were included in the study. They were randomly segregated into two 
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groups. Standard monitors like ECG, NIBP, pulse oximetry were 
connected. Anaesthesia was induced using sevoflurane 4% (inhalational 
route), then an IV cannula was inserted and atropine 0.01mg/kg 
administered. Anaesthesia was maintained with 100% oxygen/isoflurane 
2-3% with spontaneous breathing. Then caudal block was performed 
according to their group. 
 Group L - received levobupivacaine 0.25% with the dose of 
1ml/kg. 
 Group L+N - received levobupivacaine 0.25% with the dose of 
1ml/kg and nalbuphine 0.1 mg/kg. 
Hemodynamic variables, pain score and sedation score were 
recorded. The postoperative requirement of fentanyl and time to first 
analgesic requirement were noted. The authors concluded that caudal 
nalbuphine is safe in paediatric surgeries and effectively reduces 
postoperative pain. Nalbuphine may cause early postoperative sedation 
but without respiratory depression. 
  
 
Opioids
and
Opioid Receptors
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OPIOIDS 
 Opioid is derived from the Greek word opos means juice. An 
opioid is any substance regardless of its origin or structure, which acts on 
opioid receptors and produces morphine like effects that are blocked by 
antagonists such as nalaxone. It includes natural, semi synthetic and 
synthetic agents. 
 Opiates includes the natural alkaloids like morphine, thebaine and 
codeine which are derived from the juice of Papaver somniferum. 
Frederick sertuner first isolated crystalline substance from opium and he 
named as morphine in 1806. 
 
Papaver somniferum  
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ENDOGENOUS OPIOIDS 
 Endogenous opioids are found within the brain, which acts through 
opioid receptor. They are of primarily three classes - enkephalins, 
endorphins and dynorphins.  
CLASSIFICATION  
NATURAL SEMI SYNTHETIC SYNTHETIC 
Morphine Heroin Pethidine 
Codeine Dihydromorphone Pentazocine 
Thebaine Oxymorphone Fentanyl 
  Buprenorphine 
  Nalbuphine etc., 
 
USES OF OPIOIDS 
 Analgesia ( both intraoperative and postoperative) 
 As a premedicant 
 As an induction agent 
 To blunt intubation response 
 Sedation in ICU 
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 To prevent and control shivering 
 As an adjuvant to local anesthetic in intrathecal or epidural space. 
OPIOID RECEPTORS 
 Opioid receptors are the receptors which primarily mediate the 
analgesic and other effects of opioid drugs (like morphine) and 
endogenous opioid peptides. It belongs to the G protein-coupled receptor 
family. They all inhibit adenylate cyclase
[27]
 and reduce cellular cyclic 
adenosine monophosphate content. Opioid receptors are present in brain, 
spinal cord and gastrointestinal tract. 
 In the brain, opioid receptors are expressed in amygdala, 
mesencephalic reticular formation, periaqueductal gray matter, lamina I 
& IV of thalamus, mid brain and rostral ventral medulla. 
SUB TYPES OF OPIOID RECEPTORS 
 Opioid receptors
[28]
 are subdivided into three subtypes. They are 
mu(µ), kappa(κ), delta(δ). 
 mu(µ) receptors - gene on chromosome 6. They are again 
subdivided into µ1, µ2, µ3. 
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µ1 µ2 µ3 
- analgesia 
 
-respiratory depression - Vasodilation 
 
-Physical 
dependence 
- miosis,  -Increase GH and 
prolactin 
 -constipation  
 - euphoria  
 
 kappa(κ) receptors - gene on chromosome 8. They are again 
subdivided into κ 1, κ 2, κ 3. They mediates analgesia, dysphoria, 
miosis, sedation, diuresis. 
 delta(δ) receptors - gene on chromosome 1 and 4. They mediates 
analgesia, respiratory depression, dependence. 
Newer opioid receptors 
 Nociceptin receptor 
 Zetta receptor. 
Based on receptor interaction opioids are classified into pure 
agonist(+), mixed agonist/antagonist(+/-) and pure antagonist(-). 
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Pure agonist(+) 
Mixed agonist/ 
antagonist(+/-) 
Pure antagonist(-) 
morphine,  pentazocine,  naloxone,  
fentanyl,  nalbuphine,  naltrexone,  
alfentanil,  nalorphine,  nalmefene. 
pethidine , buprenorphine,   
remifentanil, butorphanol,  
sufentanil. dezocine, etc.,  
 
MECHANISM OF ACTION OF OPIOIDS 
 Opioids produce analgesia through spinal, supraspinal and 
peripheral mechanisms. 
Supraspinal    
 It activates pain control circuits (corticospinal tract), which 
descend from  midbrain via rostral ventromedial medulla to the spinal 
cord, thereby blocking nociceptive stimuli. 
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Spinal   
  They act in substantia gelatinosa of dorsal horn cells, where they 
inhibit substance P release and directly inhibit the ascending transmission 
of  nociceptive stimuli. 
Peripheral mechanisms  
  Stimulates G protein synthesis and increase cAMP which causes 
 Increased K
+ 
- Hyperpolarization of membrane 
 Decreased Ca
2+
 -     Excitability 
 
Site of action of opioids 
Pharmacology
Of
Nalbuphine
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PHARMACOLOGY OF NALBUPHINE 
 Narcotic analgesics are associated with significant abuse potential. 
To overcome the abuse potential, various synthetic opioids were 
developed. Those substances are referred to as mixed agonist-antagonist 
analgesics. Nalbuphine is one among them. 
CHEMISTRY 
 Nalbuphine hydrochloride, a synthetic narcotic agonist-antagonist 
analgesic of the phenanthrene series. Chemically, it is related to the 
opioid antagonist naloxone and opioid agonist oxymorphone. Nalbuphine 
is soluble in water at 25
o
C, ethanol 0.8% and available only as an 
injectable solution. 
CHEMICAL STRUCTURE 
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CHEMICAL NAME 
17-(cyclobutylmethyl)-4,5-epoxy-,morphinan-3,6,14-triol, 
hydrochloride 
RECEPTOR INTERACTION 
 Nalbuphine binds to mu(μ), kappa(κ), and delta(δ) receptors, but 
not to sigma receptors. Nalbuphine is primarily a κ agonist/μ antagonist 
analgesic. Nalbuphine has an analgesic potency
[29]
 similar to that of 
morphine on a milligram for milligram basis. The narcotic antagonist 
activity of nalbuphine is one-fourth(1/4
th
) as potent as that of nalorphine 
and ten times that of pentazocine. When administered subsequent or 
concurrent with µ agonist opioid analgesics (e.g., morphine, fentanyl), 
nalbuphine may partially reverse or block opioid-induced respiratory 
depression from the µ agonist analgesic. 
MECHANISM OF ACTION 
 By its agonist action, nalbuphine stimulates κ receptors thereby 
inhibiting the release of neurotransmitters like substance P that mediate 
pain. It acts as a post-synaptic inhibitor on the "inter neurons & output 
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neurons" of the Spino-thalamic tract which transport nociceptive 
information. 
PHARMACEUTICAL INFORMATION 
 Molecular formula   -  C21 H27 NO 4 .HCl 
 Molecular Mass    -  393.91 g/mol 
 pKa     -  8.71 
PHARMACOKINETICS 
 Nalbuphine is inactive orally and intravenous route is the 
conventional route of administration. It can also be administered by 
intramuscular, subcutaneous, neuraxial routes.  
 Bio-availability is around 80%.  
 Volume of distribution is 3.8litres/kg.   
   intravenous administration is within 2-3 mins 
Onset of action         
                        Subcutaneous, intramuscular < 15 mins 
Plasma half life - 5 hrs 
 Duration of analgesia - 3 to 6 hours 
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 Nalbuphine is primarily metabolised in the liver and the 
metabolites are excreted via kidney. Hence the dosage of nalbuphine 
must be decreased in patients with hepatic and renal failure. 
USES OF NALBUPHINE 
 As an adjuvant to general anesthesia 
 As an adjuvant to neuraxial anesthesia 
 Obstetric analgesia during labor and delivery 
 As an adjuvant to peripheral nerve blocks. 
 In the management of postoperative pain. 
OFF LABEL USES 
 Opioid induced pruritus. 
 Opioid induced respiratory depression[30] 
 Post anesthesia shivering 
 Sickle cell anemia with crisis 
PREPARATIONS AND STORAGE  
 Available as 10mg, 20mg solutions in 1ml ampoule. 
 Should be stored at  room temperature (15°c to 30°c). 
 Protect from excessive light. 
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Inj. Nalbuphine Ampoule 
 
ADVERSE EFFECTS 
 The most common side effects of nalbuphine are sedation, 
sweating, nausea, vomiting, dizziness, vertigo, dry mouth, headache. 
Other effects are bradycardia, hypotension, urinary urgency. Because of 
the ceiling effect,
[31]
  nalbuphine causes less respiratory depression 
compared to other opioids. It is classified as category ‘B’ (animal studies 
have failed to demonstrate fetal risk and there are no controlled studies in 
pregnant women) drug in pregnancy. It should be avoided in patients who 
are hypersensitive to the drug or its components.  
 
 
Pharmacology
Of
Bupivacaine
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PHARMACOLOGY OF BUPIVACAINE 
 Bupivacaine belongs to amide group of local anaesthetics. This 
long acting local anaesthetic was first synthesized by A.F. Ekenstam in 
1957. 
 Commercial bupivacaine is a racemic mixture of  R(dextro) and 
S(levo) stereoisomers. It is 4 times more potent than Xylocaine. It is 
available as hydrochloride salt for anaesthesia. 
CHEMICAL NAME 
 (2S)-1-Butyl-N-(2,6-dimethylphenyl)-piperidinecarboxamide 
CHEMICAL STRUCTURE 
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PHYSIO- CHEMICAL PROPERTIES 
 Molecular Formula -  C18H28N2O 
 Molecular Weight   -  290 gm/mol 
 Plasma protein binding - 95% 
 Lipid solubility  - 28 mg/L 
 Solubility in water  -  1 in 25 
 Solubility in alcohol - 1 in 8 
MECHANISM OF ACTION 
 All local anaesthetics causes blockade of voltage gated sodium 
channels, resulting in decreased entry of sodium ions into the cells 
thereby preventing depolarization. Hence the nerve signals and action 
potential cannot be propagated. 
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PHARMACOKINETICS 
 After administration it is rapidly absorbed from the injection site. 
The route of administration determines the rate of rise of plasma 
concentration as well as the peak plasma concentration. Steady state 
volume of distribution is about 70 litres and the clearance is 
approximately 0.48L/min. 
UPTAKE OF BUPIVACAINE IN SPINAL CORD 
 First method - simple diffusion from the CSF into the piamater and 
subsequently into the spinal cord. 
 Second method - by extension into the Virchow-Robin spaces 
(layers of piamater). 
METABOLISM 
 Bupivacaine  is metabolised by one of the following pathways 
 aromatic hydroxylation 
 amide hydrolysis 
 N-methyl dealkylation 
 conjugation 
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Metabolites are primarily excreted in the liver, 5-10% of the drug is 
excreted unchanged in urine. 
Onset of  action (spinal)  - 5 to 10 mins. 
Duration of spinal block  - 90 to 120 mins. 
USES 
 Central neural blockade (spinal & epidural anaesthesia) 
 Peripheral nerve blocks 
 Infiltration anaesthesia 
COMMERCIAL PREPARATIONS 
 It is available in 4ml ampoules for intrathecal injection  -  5mg/ml 
of  0.5% bupivacaine and 80mg of dextrose. 
 As 10 and 20ml vials with the concentration of 0.25%, 0.5% 
solutions. 
CONTRAINDICATIONS 
 Hypersensitivity to local anaesthetics 
 Intravenous regional anaesthesia (Bier's block) 
 Paracervical block 
Subarachnoid
Block
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ANATOMY OF SUBARACHNOID BLOCK 
 Spinal anaesthesia was introduced by AUGUST BIER in 1898. It 
involves single injection of a local anesthetic solution into the 
subarachnoid space usually at the lumbar level (commonly at L3 – L4). 
Principal site of action for central neuraxial blockade is the nerve root. 
SAB produces  
 Sympathetic blockade 
 Sensory blockade 
 Motor blockade 
 
Site of Injection of Drug 
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         The  spinal cord extends from foramen magnum (base of the skull) 
to lower border of L1 in adults, hence spinal puncture below L1 is 
advised to prevent trauma to the cord.   In children the cord extends upto 
L3 and adult level is achieved by 2 years. 
VERTEBRAL  LIGAMENTS 
Supraspinous ligament 
 
Connects the tip of each spinous 
process to the other. 
Interspinous ligament Connects the vertebral spines 
Ligamentum flavum  ("yellow 
ligament") 
Connects the lamina above and below 
Anterior Longitudinal Ligament Connects the front (anterior) of the 
vertebral body to the front of the 
annulus fibrosus. 
Posterior Longitudinal Ligament Connects the back (posterior) of the 
vertebral body to the back of the 
annulus fibrosus. 
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Vertebral Ligaments 
DERMATOLOGICAL SEGMENT  LEVELS 
 Touffier's line - Line drawn between the highest points of both iliac 
crests. It usually corresponds to L4 spine or L4-L5 interspace 
C7 
Spinous process of  7th cervical vertebrae. It is prominent 
and easily palpable. 
T4 Nipple 
T6 Xiphisternum 
T7 Inferior angle of scapula 
T10 Umblicus 
L1 Inguinal ligament 
S1 to S4 Perineum 
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BLOCK REQUIREMENTS 
Surgery Level required 
Cesarean section, Gynecologic, Intestinal surgery T6 
Transurethral resection of  prostate(TURP), 
Transurethral resection of  bladder 
tumor(TURBT) 
T10 
Knee surgery L1 
Foot and ankle surgery L2 
Perineal and anal surgery S2-S4 
 
STRUCTURES PIERCED BY SPINAL NEEDLE 
Skin 
Subcutaneous tissue 
Supraspinous ligament 
Interspinous ligament 
Ligamentum flavum 
Dura and Arachnoid 
Subarachnoid space 
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Structures encountered during spinal anaesthesia 
ADVANTAGES OF SPINAL ANAESTHESIA 
 Patient is alert during surgery 
 Lower incidence of Nausea/Vomiting/sore throat 
 Better Pain Control  
 Economical 
 Sympathectomy→ vasodilation→   ↑↑blood flow to legs →  
↓ incidence of  DVT 
INDICATIONS 
 General surgery - lower abdominal, urogenital, Inguinal & rectal 
surgery 
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 Orthopaedic surgery- all lower limb surgeries, few pelvic surgeries 
 Urologic surgery - Bladder, Prostrate and ureteric surgery 
 Gynaecologic and obstetrics surgery - Lower segment cesarean 
section, Hysterectomy, Dilatation & Curettage. 
CONTRAINDICATIONS 
 Refusal by the patient 
 Overt coagulopathy 
 Increased intracranial tension 
 Infection at injection site 
 Shock, severe hypovolemia 
 Fixed cardiac output lesions like  mital stenosis, aortic stenosis, 
complete heart block. 
TECHNIQUES 
Spinal Needles 
   
                           Dura cutting                                  Dura Separating 
               (PDPH incidence is high)                    (PDPH incidence is less) 
          -  Quincke-Babcock                               - Whitacre    
          -   Greene                                               - Sprotte 
                                                                         - Pitkin 
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Spinal needles 
Spinal needles are available in sizes ranging from 16 - 30 gauge. 
POSITIONING  
         Proper positioning is important for technical ease and 
successful block. The various positions are 
1.  Lateral decubitus  
2.  Sitting 
3.  Prone (using hypobaric drug) 
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Sitting posture 
APPROACH 
         The different approaches are 
1.  Midline approach  
 Needle is introduced in the midline and directed slightly cephalad. 
Two pop ups are felt, one is supraspinous ligament and the other is 
ligamentum flavum. The needle is advanced to penetrate the dura and 
then subarachnoid membrane as signalled by free flowing CSF. The best 
sign of correct lumbar puncture is free flowing CSF. 
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2.  Lateral or Paramedian approach 
  Indicated in patients with positioning difficulty (Kyphoscoliosis, 
Sclerotic lesions).  The needle is inserted 1cm lateral and 1cm caudal to 
the inferior aspect of spinal process. Here the first resistance felt is 
ligamentum flavum. 
 
Lateral approach 
3. Taylor's approach 
       It is a type of paramedian technique in which the needle is directed 
towards L5-S1 space. Point of insertion is 1cm medial and 1cm inferior to 
posterior superior iliac spine. Used in conditions of lumbar spine 
deformity. 
  
51 
 
Taylor's approach 
DRUGS USED 
Drug Doses Duration 
Lignocaine 5% 1-2ml 1-1.5 hr 
Bupivacaine 0.5% 2-4ml 2-4 hr 
Ropivacaine 0.75% 2-4ml 2-4 hr 
Levobupivacaine 0.5% 2-4ml 2-3 hr 
 
BARICITY OF THE SOLUTION 
 Baricity refers to the specific gravity of the local anesthetic 
solution in relation to CSF. It determine the spread of local anesthetic in 
the subarachnoid space. The specific gravity of CSF is 1.0069. 
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HYPERBARIC SOLUTIONS 
  Density of local anesthetic is greater than density of CSF. So the 
deposited drug flows to dependent sites. The position of the patient 
determines the height of block while using hyperbaric & hypobaric 
solution. 
HYPOBARIC SOLUTIONS 
 Density of local anesthetic is less than density of CSF. So the 
deposited drug flows from dependent sites. 
 
Body Position and Baricity Interaction 
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ISOBARIC SOLUTIONS 
 Density of local anesthetic is approximately equal to density of 
CSF. So the deposited drug stays there itself. The position of the patient 
has no effect. 
FACTORS AFFECTING HEIGHT OF BLOCK 
Modifiable factors 
 Dose of the drug(volume & Concentration) 
 Site of injection 
 Posture of patient 
 Baricity of  LA 
Non-modifiable factors 
 Volume of Cerebro Spinal Fluid. 
 Density of Cerebro Spinal Fluid. 
FACTORS AFFECTING DURATION OF BLOCK 
 Dose of the drug (volume & Concentration) 
 Pharmacological profile of the drug like protein binding, lipid 
solubility. 
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 Type of the drug (Bupivacaine > lignocaine) 
 Added  opioids. 
ORDER OF BLOCKING NERVE FIBER 
1. Preganglionic sympathetic B fibers 
2. Temperature (Cold > Warm) 
3. Pinprick  
4. Pain 
5. Touch 
6. Pressure 
7. Proprioception 
8. Somatic motor fibers. 
Sequence of  block is autonomic first, followed by sensory and 
then motor fibres. 
COMPLICATIONS 
 Cardiovascular disturbances like hypotension, bradycardia 
 High spinal block 
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 Local anesthetic induced neurotoxicity & neurological damage 
 Postdural puncture headache 
 Backache 
 Transient neurological symptoms (lignocaine) 
 Others- Meningitis, Arachnoiditis, Cauda equina syndrome, 
Hematoma formation. 
Materials
and
Methods
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MATERIALS AND METHODS 
 "Prospective randomized controlled study evaluating anaesthetic 
efficacy of mixture of intrathecal bupivacaine 0.5% heavy and nalbuphine 
hydrochloride with intrathecal bupivacaine 0.5% heavy alone for infra 
umbilical surgeries". 
 The study was duly submitted before the Institutional Ethical 
Committee and approval was obtained before the commencement of the 
study. 
STUDY DESIGN 
  It was a Prospective Randomized controlled study. 
SAMPLE SIZE CALCULATION 
 The study population comprised of 60 adult patients classified 
under the ASA PS 1 or 2 posted for lower abdominal surgery and lower 
limb orthopaedic surgery. 
INCLUSION CRITERIA 
 30 - 60 years of age 
 ASA physical status 1 or 2 
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 Patients who gave valid informed written consent 
 Patients undergoing lower abdominal surgery and lower limb 
orthopaedic surgery. 
EXCLUSION CRITERIA 
 Lack of valid informed written consent 
 Infection at the subarachnoid block injection site 
 Patients with neurological and musculoskeletal disease 
 Patients with bleeding disorders  
 Patients on anticoagulants 
 Pregnancy 
 History of allergy to local anaesthetic 
STUDY CENTRE & STUDY PERIOD 
 ESIC MEDICAL COLLEGE & PGIMSR, KK NAGAR, 
CHENNAI from September 2015 to June 2016. 
PRE-OPERATIVE ASSESSMENT 
 All the patients were duly examined on the day prior to surgery and 
pre-operative assessment sheet was checked. The height, weight, body 
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mass index of the patient were measured. The airway assessment, spine 
examination and the nutritional status of the patient were evaluated. 
          A detailed general and systemic examination was done. Pre-
operative investigations like complete haemogram, renal function tests, 
random blood sugar, blood grouping and typing, electrocardiography and 
chest X ray were evaluated properly. 
INFORMED WRITTEN CONSENT 
  All the patients were informed about the nature of the study and a 
valid informed written consent was obtained. 
PREMEDICATION 
          All the patients were fasted overnight and they were pre-medicated 
with tablet ranitidine 150mg, tablet metoclopramide 10mg, tablet 
alprazolam 0.5mg on the night before surgery. 
PREPARATION 
 Upon arrival to the operating room, standard monitors like non 
invasive blood pressure(NIBP), Electrocardiography(ECG) and pulse 
oximetry were connected and baseline values were recorded.  An 
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intravenous line was secured with 18G cannula and patients were 
preloaded with10ml/kg of Ringer Lactate (RL) solution. Patients were 
randomly divided into either of the two groups- Group A or Group B by 
slips in the box technique. 
MATERIALS: 
DRUGS 
 Nalbuphine Hcl - Inj 
 0.5% bupivacaine heavy - Inj 
 Normal saline  
 Emergency drugs 
EQUIPMENTS 
 25 G Quincke needle 
 Sponge holding forceps 
 Sterile 5ml & 10ml syringe 
 Sterile drape 
 Sterile gauze pieces. 
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TECHNIQUE: 
 The  patient was placed in the right lateral decubitus position. 
Under strict aseptic precautions, lumbar puncture was performed at L3-
L4 intervertebral space with 25 G quincke needle using the median 
approach. After free flow of clear cerebrospinal fluid(CSF), drug was 
injected at 0.2ml/sec. 
 Group A received 15mg (3 ml) of 0.5% bupivacaine (H) and 
nalbuphine 0.5 mg (0.5ml) - Total volume 3.5 ml. 
 Group B received 15mg (3 ml) of 0.5% bupivacaine (H) and 
normal saline 0.5 ml (0.5ml)- Total volume 3.5ml. 
 Oxygen at 4l/min was administered through face mask. 
Hemodynamic parameters like peripheral oxygen saturation, non invasive 
blood pressure, pulse rate were recorded at regular intervals 
intraoperatively and postoperatively up to 24 hours. 
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Position for Subarachnoid Block 
MONITORING 
 Hypotension - Systolic blood pressure less than 90mm Hg or less 
than  20% from baseline. Treatment given-  Inj. Mephentermine  
6mg IV bolus. 
 Bradycardia - Heart rate less than 50 beats/min. Treatment given - 
Inj. Atropine 0.6 mg. 
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BLOCK EVALUATION 
SENSORY BLOCK 
 Sensory block was assessed by pinprick method in the mid-
clavicular line using 27G needle, every minute until the block reached T6 
dermatome. After that, level was checked every 2 mins until maximal 
sensory block was attained. 
GRADES OF SENSORY BLOCKADE 
 GRADE 0  - Sharp pain felt 
 GRADE 1  - Analgesia, dull sensation felt 
 GRADE 2  - Anesthesia, no sensation felt 
Onset of sensory blockade was defined as the time interval between 
the end of anesthetic injection to loss of sensation to pinprick at T10 
level. 
MOTOR BLOCKADE 
Quality of motor block was assessed by modified Bromage scale. 
 GRADE 0 - no motor blockade,  able to lift the leg at the hip. 
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 GRADE 1 -  Able to flex the knee and ankle but not able to lift the 
leg at the hip (hip blocked)  
 GRADE 2 - Able to move the foot only (hip and knee blocked) 
 GRADE 3 - Unable to move even the foot (hip, knee and ankle 
blocked).  
Onset of complete motor blockade was defined as the time interval 
between the completion of study drug injection until Bromage 3 
registered. 
Surgery was started when complete anaesthesia was attained. After 
the completion of the surgery, both sensory and motor level were noted. 
Two segment regression time from the maximal level and regression to 
level L1 was also noted. Postoperatively, patients were regularly followed 
up in the recovery and postoperative ward for pain score using VAS 
scale. 
VISUAL ANALOG SCALE 
  Preoperatively patients were explained in detail about Visual 
Analog Scale. The scores were evaluated in the postoperative ward and 
rescue analgesia was given at a VAS score of 4 or more. 
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0-10 VAS Numeric Pain Distress Scale 
SCORE 0-2 NO PAIN 
SCORE 2-4 MILD PAIN 
SCORE 4-6 MODERATE PAIN 
SCORE 6-8 SEVERE PAIN 
SCORE 8-10 UNBEARABLE PAIN 
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PATIENT FLOW CHART 
ASSESMENT CLINIC: ASA I and ASA II (30 - 60 years of either 
sex) posted  for Infra umbilical surgeries 
 
Informed written consent obtained 
  
Patient shifted to operation theatre 
 
WHO checklist followed 
 
Groups allocated by slips in the Box technique 
 
ECG, Pulse oximetry, NIBP monitors connected 
 
IV access secured and preloaded with RL 10ml/kg 
 
Subarachnoid block performed using 25G Quincke needle 
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              Group A                    Group B 
15mg of Bupivacaine              15mg of Bupivacaine  
0.5% (H) (3ml)      0.5% (H) (3ml)     
  +                                                             + 
0.5mg Nalbuphine (0.5ml)                                Normal Saline 0.5ml
       
 
 
Block assessment 
    Sensory      -     Pin prick method 
    Motor         -     Modified Bromage scale 
 
Post-operative follow up 
Duration of analgesia- VAS scale 
 
 
Statistics
and
Results
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RESULTS AND STATISTICS 
 Sample size was calculated using n.master 2.0 software. Sample 
size based on clinical trials-parallel design-hypothesis equivalence/ 
bioequivalence. Equivalence margin  is 1, observed / expected  difference 
- 0.68, Standard deviation  - 0.5, Effect size - 0.64, Power (1-β)  - 80,  
α Error (%) - 5, Group A-30, Group B - 30. For Statistical analysis IBM 
SPSS (Version 21) software was used. The demographic data of the 
patients in both the groups were studied and the analysis revealed no 
significant difference between the two groups. 
Table-1: AGE DISTRIBUTION 
Age 
(Years) 
GROUP-A GROUP-B 
No of 
Patients 
(N) 
 
Percentage 
(%) 
No of 
Patients 
(N) 
 
Percentage 
(%) 
31 - 40 16 53.33 13 43.33 
41 - 50 12 40.00 11 36.67 
51 - 60 2   6.67 6 20.00 
TOTAL 30 100 30 100 
Chi-square 
Value 
2.35 
p-value 0.31 
Significant Not Significant 
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GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
Both the groups are identical in distribution in terms of age.  
Mean Age (in Years) 
Group  Mean Standard Deviation 
GROUP-A 39.90 7.60 
GROUP-B 42.57 8.40 
t-value 1.29 
p-value 0.20 
Significant Not Significant 
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Table-2: SEX DISTRIBUTION  
 
SEX 
GROUP-A GROUP-B TOTAL 
No of 
Patients 
(N) 
% 
No of 
Patients 
(N) 
% 
No of 
Patients 
(N) 
% 
MALE 11 36.67 12 40.00 23 38.33 
FEMALE 19 63.33 18 60.00 37 61.67 
TOTAL 30 100 30 100 60 100 
Chi-square 
value 
0.07 
p-value 0.79 
Significant  Not Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
No statistically significant difference in sex distribution between 
two groups.  
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Table-3:WEIGHT DISTRIBUTION 
Weight in kgs 
GROUP-A GROUP-B 
No of 
Patients 
(N) 
% 
No of 
Patients 
(N) 
% 
51 – 60 9 30.00   5 16.67 
61 -70 21 70.00 25 83.33 
TOTAL 30 100 30 100 
Chi-square Value 1.49 
p-value 0.22 
Significant Not Significant 
 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
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Mean Weight (Kg) 
Group Mean Standard Deviation 
GROUP-A 63.13 5.20 
GROUP-B 64.67 4.27 
t-value 1.25 
p-value 0.22 
Significant Not Significant 
 
The mean weight distribution between the two groups are similar. 
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Table-4 : HEIGHT DISTRIBUTION  
Height in cms 
GROUP- A GROUP- B 
No of 
Patients 
(N) 
% 
No of 
Patients 
(N) 
% 
151 – 160 11 36.67 12 40.00 
161 – 170 19 63.33 17 56.67 
171 –180 0 0   1  3.33 
TOTAL 30 100 30 100 
Chi-square Value 1.16 
p-value 0.56 
Significant Not Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
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Mean Height (Centimeter) 
Group Mean Standard Deviation 
GROUP-A 162.60 4.52 
GROUP-B 162.30 4.94 
t-value 0.25 
p-value 0.81 
Significant Not Significant 
 
The mean height distribution between the two groups are similar. 
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Table-5: ASA DISTRIBUTION 
 
ASA 
GROUP-A GROUP-B 
No of 
Patients 
(N) 
% No of 
Patients 
(N) 
% 
I 23 76.67 21 70.00 
II 7 23.33 9 30.00 
TOTAL 30 100 30 100 
Chi-square Value 0.34 
p-value 0.56 
Significant Not Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
ASA - American Society of Anesthesiologist 
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Table-6:PRE-OPERATIVE VITALS 
 
Variables 
GROUP-A GROUP-B t-
value 
p-
value 
Significant 
MEAN SD MEAN SD 
PR 
(Min) 
85.20 4.39 85.00 4.09 0.18 0.86 NS 
SBP 
(mmHg) 
121.33 7.45 122.33 8.02 0.50 0.62 NS 
DBP 
(mmHg) 
79.13 4.33 78.97 3.38 0.17 0.87 NS 
SPO2 % 
 
100 0 100 0 - - - 
NS-Not Significant 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
No statistically significant difference between the two groups in 
terms of  preoperative vitals. 
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STUDY PERIOD  
Table-7:PULSE RATE (beats/min)  
TIME 
 
GROUP-A GROUP-B t-
value 
p-
value 
Significant 
MEAN SD MEAN SD 
2 Sec 88.47 4.00 86.63 4.23 0.16 0.88 NS 
2 Min 89.30 3.64 89.23 3.14 0.08 0.94 NS 
4 Min 90.70 4.04 91.47 3.49 0.79 0.44 NS 
6 Min 91.27 4.74 91.53 3.96 0.24 0.81 NS 
8 Min 89.17 5.36 90.80 5.32 1.19 0.24 NS 
10 Min 85.97 5.70 86.70 5.33 0.52 0.61 NS 
15 Min 81.57 6.29 83.00 5.02 0.98 0.33 NS 
20 Min 78.67 5.88 80.07 5.30 0.97 0.34 NS 
25 Min 76.03 6.57 76.37 5.01 0.22 0.83 NS 
30 Min 73.00 7.05 74.30 5.25 0.81 0.42 NS 
40 Min 70.67 7.47 71.70 6.25 0.58 0.56 NS 
50 Min 68.67 7.01 69.43 4.57 0.50 0.62 NS 
1 Hour 67.73 5.51 69.50 5.85 1.20 0.23 NS 
2 Hour 70.93 5.08 72.83 6.49 1.26 0.21 NS 
3 Hour 74.80 6.04 77.27 6.06 1.59 0.12 NS 
4 Hour 77.83 6.11 82.73 5.60 3.24 0.002 Significant 
5 Hour 81.30 5.77 86.37 4.45 3.81 0.001 Significant 
6 Hour 84.30 5.47 88.67 4.71 3.31 0.002 Significant  
8 Hour 85.50 5.33 89.00 3.92 2.90 0.005 Significant 
10 Hour 87.53 4.62 90.27 4.39 2.34 0.002 Significant 
12 Hour 89.00 4.47 91.53 3.93 2.33 0.002 Significant 
14 Hour 88.57 3.36 90.03 5.73 1.21 0.23 NS 
16 Hour 88.47 3.09 89.80 5.39 1.18 0.25 NS 
18 Hour 88.93 3.81 90.01 4.05 1.13 0.04 NS 
20 Hour 89.67 4.06 90.07 3.64 0.30 0.05 NS 
22 Hour 90.73 3.37 91.00 3.17 0.36 0.75 NS 
24 Hour 90.40 2.82 91.87 4.24 1.58 0.12 NS 
NS- Not Significant 
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GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 From the above graph, it was clearly evident that the mean pulse 
rate for the first three hours after spinal anaesthesia was similar in both 
the groups, after that patients in the nalbuphine group had significantly 
lower pulse rate than the control group from 4 to 10 hours.  
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Table-8:SYSTOLIC BLOOD PRESSURE (mm Hg) 
TIME 
 
GROUP-I GROUP-II 
t-value p-value Significant 
MEAN SD MEAN SD 
2 Sec 121.93 6.81 121.63 7.01 0.17 0.87 NS 
2 Min 119.10 6.28 119.13 6.38 0.02 0.98 NS 
4 Min 116.37 6.17 116.33 6.22 0.02 0.98 NS 
6 Min 113.07 7.24 112.27 5.83 0.47 0.64 NS 
8 Min 109.43 7.61 108.80 7.74 0.34 0.73 NS 
10 Min 106.70 7.82 106.00 6.25 0.38 0.73 NS 
15 Min 105.03 6.25 104.50 6.27 0.33 0.74 NS 
20 Min 103.87 4.52 103.27 5.34 0.47 0.64 NS 
25 Min 104.13 5.53 103.10 4.58 0.79 0.43 NS 
30 Min 103.50 4.78 104.10 5.41 0.46 0.65 NS 
40 Min 104.70 5.93 104.50 4.95 0.14 0.89 NS 
50 Min 104.37 5.82 105.07 5.19 0.49 0.63 NS 
1 Hour 106.43 5.38 108.03 5.47 1.14 0.26 NS 
2 Hour 107.50 7.78 111.40 4.94 3.11 0.003 Significant 
3 Hour 111.30 6.39 114.90 5.09 2.41 0.02 Significant 
4 Hour 114.83 6.24 119.00 5.73 2.40 0.001 Significant 
5 Hour 117.47 5.85 121.37 4.43 2.42 0.02 Significant 
6 Hour 118.13 5.45 120.97 5.15 1.84 0.003 Significant 
8 Hour 121.97 57.74 122.43 6.45 0.30 0.77 NS 
10 Hour 121.70 6.06 121.60 6.55 0.06 0.95 NS 
12 Hour 121.83 5.81 121.47 5.07 0.26 0.80 NS 
14 Hour 120.93 5.33 122.33 6.13 0.94 0.35 NS 
16 Hour 119.73 4.84 121.03 5.86 0.94 0.35 NS 
18 Hour 121.90 4.41 123.90 5.13 1.62 0.11 NS 
20 Hour 121.17 4.74 122.40 5.33 0.95 0.35 NS 
22 Hour 121.10 4.88 122.13 5.51 0.77 0.45 NS 
24 Hour 122.03 4.17 123.50 5.13 1.22 0.23 NS 
NS – Not Significant 
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Table-9:DIASTOLIC BLOOD PRESSURE (mm Hg) 
TIME 
 
GROUP-I GROUP-II 
t-value 
p-
value 
Significant 
MEAN SD MEAN SD 
2 Sec 79.67 3.98 78.93 3.36 0.77 0.73 NS 
2 Min 78.30 2.91 77.70 2.58 0.85 0.40 NS 
4 Min 76.73 3.25 75.47 4.49 1.25 0.22 NS 
6 Min 74.40 5.26 74.23 4.58 0.13 0.90 NS 
8 Min 73.07 5.22 72.07 5.56 0.72 0.48 NS 
10 Min 70.87 6.68 69.70 4.45 0.80 0.43 NS 
15 Min 69.23 6.72 67.90 5.42 0.85 0.40 NS 
20 Min 67.03 5.49 67.57 5.73 0.37 0.71 NS 
25 Min 67.70 4.85 68.37 5.03 0.52 0.60 NS 
30 Min 68.50 5.91 68.27 5.94 0.15 0.88 NS 
40 Min 68.97 6.82 69.07 4.31 0.07 0.95 NS 
50 Min 68.80 6.20 70.80 4.59 1.42 0.16 NS 
1 Hour 70.97 5.64 72.00 4.64 0.78 0.44 NS 
2 Hour 72.07 5.55 76.47 4.79 2.79 0.003 Significant 
3 Hour 73.97 4.71 77.53 5.06 2.24 0.001 Significant 
4 Hour 74.40 5.61 78.20 4.01 3.02 0.004 Significant 
5 Hour 77.10 5.33 79.63 3.21 2.23 0.03 Significant 
6 Hour 77.90 3.99 79.33 3.08 1.56 0.12 NS 
8 Hour 78.83 3.50 79.90 3.41 1.20 0.24 NS 
10 Hour 78.87 3.69 79.67 3.34 0.88 0.38 NS 
12 Hour 79.43 3.72 79.70 4.40 0.25 0.80 NS 
14 Hour 79.03 4.61 79.50 3.29 0.45 0.65 NS 
16 Hour 79.13 3.34 80.00 2.73 1.37 0.42 NS 
18 Hour 79.77 2.89 80.10 2.51 0.48 0.64 NS 
20 Hour 78.97 3.80 79.73 2.91 0.88 0.38 NS 
22 Hour 78.93 3.51 79.90 3.45 1.07 0.29 NS 
24 Hour 79.90 2.81 80.87 3.08 1.27 0.21 NS 
NS-Not Significant 
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GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 These graphs shows that the mean systolic pressure (SBP) and 
diastolic blood pressure (DBP) were comparatively low in the nalbuphine 
group than the control group from 2 to 6 hrs. 
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Table-10:TIME TO ONSET OF SENSORY BLOCK AT T10(MINS) 
Group  Mean Standard Deviation 
GROUP-A 1.93 0.45 
GROUP-B 3.30 0.54 
t-value 10.71 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 Mean onset time of  sensory block in group A (Nalbuphine) was 
1.93± 0.45mins and found to be significantly earlier than group B. 
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Table-11: MAXIMAL SENSORY BLOCK ATTAINED 
SENSORY 
BLOCK 
ATTAINED 
GROUP-A GROUP-B 
No of 
Patients (N) 
% 
No of 
Patients (N) 
% 
T4 20 66.67 3 10.00 
T6 10 33.33 27 90.00 
TOTAL 30 100 30 100 
Chi-square value 20.38 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 More number of patients in group A attained maximal sensory 
block (T4) than group B and was found to be statistically significant. 
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Table-12:TIME TO ONSET OF MOTOR BLOCKADE (MINS) 
Group  Mean Standard Deviation 
GROUP-A 2.97 0.56 
GROUP-B 4.50 0.63 
t-value 9.99 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
Mean onset time of  motor block in the nalbuphine group was 
2.97± 0.56 minutes and was found to be significantly earlier than  
group B. 
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Table-13:TIME TO REGRESSION OF SENSORY BLOCK UPTO 
L1(hr) 
Group  Mean Standard Deviation 
GROUP-A 4.65 1.03 
GROUP-B 3.21 0.57 
t-value 6.86 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
Mean time to regression of sensory block upto L1 was 
4.65±1.03hrs in nalbuphine group and found to be significantly longer 
than the control group which was 3.21±0.57hrs. 
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Table-14:DURATION OF MOTOR BLOCKADE  
(BROMAGE 1)(hrs) 
Group  Mean Standard Deviation 
GROUP-A 2.87 0.39 
GROUP-B 2.05 0.34 
t-value 7.66 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
Mean duration of motor blockade in group A (Nalbuphine) was 
2.87±0.39hrs and in group B was 2.05±0.34hrs. This shows significant 
prolongation of motor block in nalbuphine group. 
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Table-15: DURATION OF ANALGESIA (Hrs) 
Group  Mean Standard Deviation 
GROUP-A 5.54 1.05 
GROUP-B 3.62 0.61 
t-value 7.00 
p-value 0.000 
Significant Significant 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 The mean duration of analgesia in the nalbuphine group was 
5.54±1.05 hrs  and found to be significantly longer than control group 
(3.62±0.61hrs). 
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Table-16: SIDE EFFECTS 
Side effects 
GROUP-A GROUP-B 
No of 
Patients 
% 
No of 
Patients 
% 
Nil 18 60.00 20 66.66 
Hypotension (H) 6 20.00 6 20.00 
Nausea (N) 0 0 2  6.67 
Shivering (S) 6 20.00 2  6.67 
TOTAL 30 100 30 100 
Chi-square value 4.11 
p-value 0.25 
Significant Not Significant 
 
 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
The side effects reported between the two groups was not 
statistically significant. Hence nalbuphine can be safely administered 
intrathecally.   
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Table-17: VAS SCORES 
Time (mins) 
Group A Group B 
Mean SD Mean SD 
60 0 0 0 0 
90 0 0 0 0 
120 0 0 0.61 0.56 
150 0 0 1.22 0.27 
180 0.51 0.55 2.14 0.22 
210 1.16 0.23 3.47 0.15 
240 2.08 0.2 R 
 
270 3 0.13 
  
300 3.15 0.23 
  
330 3.47 0.05 
  
360 R 
   
(R - Rescue Analgesic, VAS - Visual Analog Scale) 
 
GROUP A - BUPIVACAINE + NALBUPHINE 
GROUP B - BUPIVACAINE + NORMAL SALINE 
 Patients in the nalbuphine group had less mean VAS scores 
compared to control group.  
Discussion
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DISCUSSION 
 Over the years, extensive  research  have been done to improve the 
quality of spinal anaesthesia by varying drug regimens and technical 
methods. Normally adjuvants are added  to hyperbaric bupivacaine 0.5% 
and administered intrathecally to prolong the anaesthetic effects. They 
produce antinociceptive effect by acting perineurally or at different 
receptor sites in the spinal cord.  
 Intrathecal opioids when used as adjuvants are capable of 
producing early onset of sensory, motor blockade and prolonged 
postoperative analgesia. They also allow early ambulation of patients due 
to their sympathetic and motor sparing activities.  
 Nalbuphine hydrochloride is a mixed μ antagonist and κ agonist 
opioid. It has been found to cause prolongation of the effects of local 
anaesthetics in intrathecal, epidural and peripheral nerve blocks with the 
advantages of minimal respiratory depression and better hemodynamic 
stability. 
 This prospective randomised controlled study performed in 60 
patients who underwent infraumbilical surgeries under spinal anaesthesia 
demonstrated that nalbuphine in the dose of 0.5mg when added to 
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hyperbaric bupivacaine had earlier onset of sensory and motor blockade 
and prolonged duration of analgesia. 
 Both the study and control groups were comparable in 
demographic parameters like age, weight and height. The mean age of the 
patients in the nalbuphine group (A) was 39.90±7.60 years. The mean age 
of the patients in the control group (B) was 42.57±8.40 years. The mean 
weight of the patients in the nalbuphine group was 63.3±5.20 kgs. The 
mean weight of the patients in the control group was 64.67±4.27 kgs. The 
mean height of the patients in the nalbuphine group was 162±4.52 cm. 
The mean height of the patients in the control group was 162.30±4.97 cm. 
The variables were compared using independent sample test and Levene's 
test for equality of variances and p value was found to be not significant. 
 The mean pulse rate of the patients in the nalbuphine group  was 
around 77 bpm whereas in the control group it was around 83 bpm at 
4
th
hour. The systolic and diastolic pressures of the patients in the 
nalbuphine group were 114±6.24 mmHg and 74.40±5.61 mmHg 
respectively, whereas in the control group it was around 119±5.73 mmHg 
and 78.20±4.01 mmHg at 4
th
 hour. Statistical analysis of the mean blood 
pressure and mean pulse rate was done and p value was found to be 
significant between 3 to 6 hrs. 
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 The sensory and motor block were checked after performance of 
subarachnoid block using pinprick and modified Bromage scale 
respectively. The mean onset time of sensory block (T10) in the 
nalbuphine group was found to be 1.93±0.45 mins whereas in the control 
group it was found to be 3.30±0.54 mins. The mean onset time of motor 
block was found to be 2.97±0.56 mins in the nalbuphine group whereas in 
the control group it was found to be 4.50±0.63 mins. The statistical 
analysis by the independent sample test and the t test for equality of 
means has shown faster onset time for sensory and motor block 
significantly with a p value of 0.0001 in the nalbuphine group. More 
number of patients in the nalbuphine group (A) achieved higher sensory 
level (T4) than the patients in the control group (B). 
 The mean time to regression of sensory block upto L1 in the 
nalbuphine group was found to be 4.65±1.03 hrs, whereas in the control 
group it was found to be 3.21±0.57 hrs. Mean duration of motor blockade 
in the nalbuphine group was 2.87±0.39hrs and in the control group was 
2.05±0.34hrs. Statistical analysis were done and p value (0.0002) was 
found to be significant.  
 The patients were followed in the postoperative period for the 
presence of pain by the Visual Analog Scale. The VAS score of 4 is 
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considered as the termination of analgesia. When the patients had a VAS 
score of 4 rescue analgesic (1g IV paracetamol) was given. The mean 
duration of analgesia in the nalbuphine group was found to be 5.54±1.05 
hrs and in the control group it was found to be 3.62±0.61hrs. Statistical 
analysis revealed significant p value (0.0001) between the two groups. 
 Shakooh
[10]
 et al in their study of 60 patients had demonstrated 
similar faster onset of sensory and motor block - 1.43±0.57 minutes and 
3.47±1.01 minutes respectively on addition of 0.8mg of nalbuphine to 
0.5% hyperbaric bupivacaine. They also demonstrated significant 
(p<0.05) prolongation of  the duration of  two segment sensory regression 
& motor blockade - 218.50±34.72 mins and 243.3±56.46 mins. The 
duration of postoperative analgesia in their study was 298±51.02 mins. 
Side effects like bradycardia and urinary retention were not reported. 
Hence in our study, we decided to add a low dose of nalbuphine 
intrathecally to hyperbaric bupivacaine  to produce desired results 
without adverse effects. The results obtained in this study was 
comparable with them. 
 Pallavi Ahluwalia
[23]
 et al in their study of 70 patients demonstrated 
that the onset time of sensory block was found to be  earlier in nalbuphine 
group (1.29±0.43 mins) compared to the control group (3.78±1.31mins). 
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The duration of motor blockade and the duration of analgesia in the 
nalbuphine group  were 256.41 mins and 298.43 mins. We obtained 
similar results in our study.  
 Mukherjee
[8]
 et al formulated 'a study to determine whether 
nalbuphine prolongs analgesia by comparing with control group and also 
to determine the optimum dose of intrathecal nalbuphine'. It was observed 
that 0.4mg of nalbuphine  with  0.5% hyperbaric bupivacaine produces 
prolongation of the duration of postoperative analgesia without any side 
effects. Hence we used 0.5mg of nalbuphine intrathecally. 
 Lin
[12] 
et al demonstrated 'the analgesic effect of subarachnoid 
administration of tetracaine combined with 0.4 mg of nalbuphine or 0.4 
mg of morphine'. They reported 0.4 mg of nalbuphine or morphine 
improves the effectiveness of intraoperative and postoperative analgesia 
but the side effects are less in nalbuphine group compared to morphine 
group. In our study we added nalbuphine to bupivacaine intrathecally and 
obtained similar quality of analgesia. 
 Intrathecal nalbuphine was in practise over 20 years with no 
neurotoxic side effects. Earlier studies have been conducted on parturient 
women did not reveal any untoward effects. There was an animal study 
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by Rawal
[32]
 et al that examined the effects of intrathecal nalbuphine and 
reported no behavioral and systemic histo-pathologic abnormalities . 
 All the patients in our study both nalbuphine and control groups 
were monitored in the postoperative period and oxygen was 
supplemented at the rate of 2 litres/minute through ventimask. 
 
 
 
 
 
Conclusion
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CONCLUSION 
 Nalbuphine hydrochloride in the dose of 0.5mg when added as an 
adjuvant to hyperbaric bupivacaine 0.5% in subarachnoid block had a 
faster onset of sensory and motor blockade. The two segment dermatome 
regression time was significantly prolonged and the duration of 
postoperative analgesia was also increased in nalbuphine group. There 
was no increase in the risk of side effects like pruritus, hypotension, 
bradycardia and urinary retention. 
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PROFORMA 
  
Name of the patient:                                         Age:                     
Sex:          Group:   
Weight:                                         Height:                        
Insurance No:                       Diagnosis:         
Date:          Procedure: 
Anaesthetic plan:                                 Anaesthetist: 
Surgeon:                    OT: 
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PREOP:      PR:                      NIBP:                             Spo2:         
Temp.                    RR:   
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INTRAOPERATIVE  DETAILS 
Time of spinal drug  injection                                Space  
Drug                                              Needle  
Time to onset of sensory block at T10  
Maximal sensory block attained  
Time to onset of maximal sensory block  
Time to onset of motor block (Bromage 3)  
Maximal motor block attained  
 
 
POSTOPERATIVE DETAILS 
Time to regression of sensory block (upto L1)  
Duration of analgesia  
Rescue analgesic                             Time  
Duration of motor blockade (Bromage 1)  
Time to first spontaneous micturition  
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SIDE EFFECTS NOTED: 
 
TREATMENT GIVEN: 
  
PATIENT CONSENT FORM 
STUDY TITLE  
A prospective randomized controlled  study comparing  anaesthetic 
efficacy of mixture of  intrathecal nalbuphine hydrochloride and 
bupivacaine 0.5% heavy with  bupivacaine 0.5 %heavy alone for 
infraumbilical surgeries.                              
STUDY CENTRE  
 ESIC MEDICAL COLLEGE & PGIMSR, K.K.NAGAR, CHENNAI -78  
PARTICIPANT  NAME :                      
AGE:                          SEX:              
I confirm that I have understood the purpose of procedure for the 
above study . I have the opportunity to ask the question and all my 
questions and doubts have been answered to my satisfaction.  
I have been explained about the pitfalls in the procedure.  I have 
been explained about the safety, advantage and disadvantage of the 
technique. I understand that my participation in the study is voluntary and 
that I am free to withdraw at anytime without giving any reason. 
  
 I understand that  investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both 
in respect to current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study . I understand that my 
identity will not be revealed in any information released to third parties or 
published , unless as required under the law. I agree not to restrict the use 
of any data or results that arise from the study.   
I understood that I will receive drugs to prolong the duration of 
analgesia using nalbuphine in subarachnoid block. I have been explained 
that the anesthetic technique is a standard and approved technique. This 
may help in future research in the field of anesthesia. I consent to undergo 
this procedure. 
  
INSURANCE NO:  
DATE:                                                                           
Signature / thumb impression of patient  
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Master Chart
  
KEY TO MASTER CHART 
 
GROUPS 
GROUP A  = Bupivacaine + Nalbuphine 
GROUP B  = Bupivacaine + Normal Saline 
PARAMETERS 
ON-SB        =   onset of sensory block 
MAX-SB     =  maximum sensory block  level  
ON-MB       =  onset of motor block 
REG-SB      =   regression of sensory block upto L1 
DU-MB       =  duration of motor block 
DU-ANAL  = duration of analgesia 
PR                =  pulse rate 
SBP              = systolic blood pressure 
DPB             = diastolic blood pressure 
SI-EF           = side effects 
N  = Nausea 
H  = Hypotension 
S  = Shivering 
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80
82 78
A 0
ELUMALAI 45 M 154
55 B I 4 T8 7 1 3 5 4 4.58 5 78
68 70 76 76 70 73 78 72 64 68 65 60 78 74 78 76 81 82 82 86 87 80 83 84 76 73 75
121
125 120 123 124 120 114 118 116 115 114 110 111 112 118 116 114 120 122 123 120 124 126 128 124 120 122 120 88 80 90 86 84 82 82 85 80 75 78 75 71 72 82 80 83 84 85 82 80 84 80 88 80
81
80 82
A S
KESAVAN 60 M 154
56 B II 5 T6 10 2 2 12 3.3 3.2 2.9 98
96 99 98 93 90 90 84 85 88 74 75 78 75 72 72 71 72 72 76 74 78 74 70 72 74 80 82
130
132 134 128 130 132 131 133 128 127 124 124 126 124 127 126 128 125 121 122 126 124 129 120 120 126 124 118 80 81 82 87 83 81 87 70 76 84 80 71 74 74 82 80 76 81 81 83 83 84 82 85 80
80
82 81
A 0
DAKSHINAMOORTHY 50 M 150
53 B I 3 T8 6 2 3 14 4 4.47 5.33 64
65 70 75 71 75 72 78 77 64 60 62 61 72 72 78 74 80 81 82 87 86 82 84 81 78 72 76
119
121 118 120 123 122 114 120 115 116 112 111 111 110 120 121 120 112 124 122 120 123 120 128 118 120 120 116 82 80 94 90 84 82 82 86 80 78 77 74 70 70 80 81 80 82 86 80 80 81 80 85 80
81
80 82
A 0
LAKSHMANAN 47 M 154
52 B I 3 T6 10 4 3 8 5.5 6 5.13 88
86 66 67 76 76 79 82 80 69 70 71 65 65 64 62 66 65 70 70 71 71 72 70 70 76 76 78
132
120 124 119 107 106 106 104 106 106 107 103 102 101 102 105 104 121 121 120 126 122 120 120 120 118 122 120 95 76 76 78 70 68 68 67 67 68 65 65 64 66 65 68 64 72 71 70 68 70 73 74 76
75
69 70
A 0
MOHAN 31 M 154
65 B I 3 T6 9 3 3 15 3.13 2.97 3.33 90
91 92 92 87 82 91 88 91 88 92 71 91 92 92 86 86 82 82 81 84 88 88 91 92 95 91 86
125
128 135 138 130 128 118 116 110 99 101 88 115 116 115 118 112 112 118 120 121 120 122 119 122 123 128 130 82 80 88 86 78 74 71 72 66 70 69 48 65 68 66 64 66 71 72 72 74 81 83 80 85
88
71 80
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ARUN KUMAR 23 M 155
58 B II 4 T6 10 2 3 5 3 3.3 2.67 86
88 90 82 84 88 76 78 75 78 80 82 78 75 72 72 74 74 78 76 74 74 78 70 70 80 78 80
128
126 124 120 128 126 124 120 120 118 124 120 120 114 118 120 116 124 120 120 126 124 126 118 120 124 122 120 82 80 82 86 82 80 78 72 74 84 82 78 74 76 80 82 84 82 80 80 84 82 84 88 82
80
80 78
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THANGAM 46 F 156
55 B II 1 T8 2 3 3 5 3 4.08 4 104
104 103 104 102 101 100 102 85 88 86 88 90 92 96 98 94 86 88 84 82 86 84 82 86 84 80 80
150
140 145 144 140 140 138 130 138 135 130 135 130 128 124 120 128 128 120 120 120 120 126 126 126 126 120 120 92 92 90 92 90 90 84 80 86 87 86 86 88 74 76 74 70 72 80 82 80 80 80 82 80
84
80 78
A 0
GANESAN 51 M 155
60 B II 4 T6 6 3 3 4 4.67 5 5.83 90
88 84 86 84 72 78 76 76 74 78 70 72 82 82 84 88 80 80 82 80 84 82 78 76 70 72 74
128
128 126 122 122 124 126 128 120 118 120 110 116 118 120 122 121 124 122 124 122 121 120 124 122 124 122 118 82 84 82 76 72 78 72 74 72 70 82 78 74 76 78 78 82 80 82 80 82 80 82 80 82
84
82 78
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CHANDRAN 64 M 160
65 B II 5 T6 6 4 3 6 4.63 5 4.3 70
74 68 66 64 64 60 62 58 60 62 68 67 64 66 68 66 68 64 68 66 68 70 72 74 72 72 70
124
124 126 122 120 116 121 120 120 122 124 120 122 126 125 126 124 120 118 114 116 122 120 124 120 118 118 122 86 88 82 90 84 88 87 86 88 84 86 80 82 84 80 82 84 86 80 82 84 88 82 80 82
82
86 84
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SUNDAR 27 M 160
50 B I 4 T6 5 4 3 8 3.17 3.13 3.33 92
94 88 86 88 82 89 84 85 86 78 78 78 76 74 74 72 74 74 76 78 78 72 74 72 78 82 84
128
128 130 128 125 130 128 130 128 126 124 122 126 124 126 128 126 124 120 122 124 122 126 122 124 126 120 118 82 80 82 86 84 80 86 80 74 72 78 72 74 72 80 82 78 80 80 78 80 82 80 84 82
84
82 80
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PONNAMMAL 38 F 158
55 B II 2 T6 2 3 3 5 3.13 3.17 3.07 88
86 82 85 78 70 74 80 82 80 78 70 78 72 72 72 74 70 72 74 72 78 74 70 78 74 80 82
124
128 126 130 136 132 134 132 128 126 122 124 122 120 128 124 126 122 120 118 116 120 128 122 122 126 124 120 84 85 84 84 86 82 78 72 74 82 80 70 74 76 72 82 80 84 82 80 74 82 84 78 78
82
84 78
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VENKATESAN 21 M 160
58 B I 2 T6 5 2 3 12 3.33 4.17 5 68
68 70 72 70 74 70 78 78 70 78 68 68 70 72 78 74 82 82 84 88 86 82 88 82 78 76 74
120
122 118 120 122 120 118 118 116 116 114 110 121 118 120 122 120 118 122 124 122 122 120 124 120 122 124 118 80 82 80 88 84 86 82 84 82 78 78 76 72 74 82 82 84 80 84 82 82 80 78 80 82
80
82 84
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ELUMALAI 41 M 160
58 B II 3 T4 4 2 3 4 4.33 5 6 74
76 72 68 66 66 66 68 68 66 66 64 68 67 68 66 70 72 74 72 70 72 76 72 74 72 76 78
128
122 112 110 112 110 98 100 102 104 100 106 110 112 114 108 108 110 112 116 126 122 128 126 124 126 122 124 80 84 78 68 68 70 72 70 68 72 70 72 68 68 72 74 76 70 74 72 80 82 82 80 82
80
82 80
A 0
GANESH BABU 36 M 155
55 A II 5 T4 12 2 3 6 4.47 4.27 4 108
98 92 96 90 88 86 88 85 79 72 81 82 75 72 70 76 74 72 76 74 78 70 68 66 69 72 74
140
140 130 122 120 122 112 115 98 93 92 85 99 99 100 102 104 105 108 110 112 120 120 122 120 120 120 120 90 90 86 82 72 70 64 66 65 59 58 51 56 61 68 64 66 68 64 70 72 76 70 80 82
82
80 84
A NH
BANUMATHY 48 F 156
60 A I 7 T6 12 4 3 6 3.3 3.18 3.05 93
92 94 91 92 90 82 84 86 82 72 76 78 74 76 74 72 70 68 72 70 68 82 84 86 88 78 74
124
122 118 115 112 110 110 108 107 105 110 98 86 98 110 116 112 110 108 106 104 112 120 122 120 124 120 120 88 86 85 72 70 68 67 64 66 68 70 66 61 70 72 84 72 70 72 74 74 78 84 80 80
82
80 86
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PALANI 37 M 166
55 A I 4 T6 8 1 3 3 4.2 6.2 4.7 92
92 88 86 92 93 90 91 92 96 90 92 93 92 86 88 84 82 86 82 80 83 82 84 80 86 88 84
130
130 126 121 119 118 120 121 126 122 118 110 115 112 113 114 115 120 121 120 122 120 128 120 126 124 122 121 80 80 82 80 82 80 86 90 86 82 76 74 76 74 76 72 70 76 78 80 82 81 86 80 79
72
73 80
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PITCHANDI 54 M 160
65 A I 8 T8 12 6 3 25 4.95 5.11 4 86
86 88 90 92 91 92 82 76 70 72 69 71 70 72 68 64 62 64 66 68 70 71 72 73 80 81 74
143
146 150 155 152 150 152 140 137 130 132 133 131 130 132 120 122 100 124 120 122 120 128 126 124 120 124 124 92 91 100 102 101 100 102 92 96 90 91 93 91 90 92 80 86 60 82 84 82 80 82 80 82
80
80 86
A 0
MURUGESAN 54 M 150
50 A I 7 T6 10 6 3 8 5 6 5 62
62 62 63 62 60 56 58 42 66 74 86 88 90 92 86 88 84 80 76 74 72 70 74 76 78 72 74
122
122 120 110 112 108 109 110 100 112 132 131 130 128 124 120 126 122 110 110 112 118 120 120 124 124 126 120 86 86 82 72 70 68 67 72 68 67 82 86 80 84 82 80 84 80 70 72 70 74 80 80 84
84
82 80
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RAMANI 50 F 152
70 A II 3 T6 4 2 1 5 5 5.2 5 114
114 122 124 130 110 84 82 85 83 85 87 88 86 84 90 92 86 84 80 82 80 74 76 72 74 76 78
140
140 134 130 119 103 99 92 97 96 97 96 98 100 110 112 118 116 120 124 122 126 120 124 128 124 120 122 92 92 92 90 64 60 57 53 58 56 58 56 54 62 72 70 74 74 80 82 80 84 82 82 86
80
80 82
A H
SUDHAM JENA 28 M 158
50 A I 4 T4 10 2 3 8 4.9 5.9 3.9 93
93 80 82 86 84 88 72 66 54 58 60 61 63 68 67 65 66 68 67 68 72 70 82 80 81 82 80
126
129 136 139 125 120 112 108 84 101 102 100 98 97 101 108 102 110 112 118 110 110 112 120 122 124 126 122 89 86 83 75 73 70 68 60 50 69 68 67 68 65 68 67 68 67 70 72 76 74 80 82 86
84
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RAMESH 40 M 156
55 A I 1 T6 2 1 3 3 4.41 4.17 4.33 92
92 87 86 78 71 68 65 66 67 61 62 62 58 55 62 66 68 70 72 74 76 74 82 80 81 82 84
128
129 117 111 100 96 94 94 94 93 94 93 93 97 98 101 108 110 112 114 112 110 114 112 110 112 110 112 82 82 76 73 70 56 57 56 54 58 57 57 61 64 62 72 70 72 78 76 70 70 70 68 69
78
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THIRUMOORTHY 27 M 170
68 A I 1 T4 8 1 3 2 2.98 3.23 2.23 83
81 80 76 66 65 64 61 59 57 63 62 61 57 67 66 68 67 70 72 74 80 82 86 80 84 86 80
123
123 120 94 101 100 101 101 100 98 92 97 98 96 95 100 104 106 108 112 114 110 120 122 123 124 126 120 90 92 90 50 49 50 50 52 52 51 51 50 51 51 53 54 60 62 68 64 66 68 70 72 74
75
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LAKSHMANAN 22 M 168
55 A I 7 T6 9 4 3 6 4.89 4.88 4.43 86
86 87 88 84 80 86 84 84 86 78 68 66 60 64 68 72 76 80 82 90 83 84 86 80 88 88 86
122
122 120 121 114 110 112 110 112 108 110 101 97 100 101 112 114 116 122 120 120 122 120 126 124 120 120 122 82 82 80 76 82 78 76 70 76 68 70 80 74 70 68 72 70 72 80 86 84 82 80 82 84
82
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SRINIVASAN 51 M 162
60 A II 7 T6 10 3 3 9 4 5.23 4 86
88 86 87 92 96 93 88 80 84 86 79 81 77 79 93 90 88 92 79 93 90 72 70 68 72 74 70
130
132 129 125 122 121 114 112 114 110 108 103 101 105 100 105 104 100 104 108 110 114 120 122 124 120 121 120 90 92 94 92 92 90 80 76 74 68 70 71 70 72 72 77 70 68 67 72 78 72 80 86 84
82
86 80
A S
SUGUNA 34 F 156
65 A I 1 T6 3 5 3 6 2.87 3.11 3.3 98
97 98 92 100 91 97 96 88 84 78 77 90 78 88 84 86 88 82 84 80 86 82 80 84 78 74 76
130
129 121 118 116 116 117 116 114 112 114 116 109 103 106 108 104 106 108 110 112 116 114 120 122 121 123 118 89 85 76 74 73 74 77 75 72 74 72 68 73 70 67 68 65 66 70 71 72 74 73 74 70
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GOPAL 49 M 160
55 A II 15 T4 20 5 3 6 3.4 3.5 4 77
77 72 66 62 68 69 72 70 68 66 68 68 70 71 72 71 70 72 76 74 78 74 76 78 72 70 88
148
148 136 132 130 130 127 121 120 122 121 118 113 112 110 112 114 116 118 120 122 120 121 122 123 125 126 128 95 95 92 88 84 80 81 86 843 86 84 78 77 76 74 75 76 73 72 70 72 74 76 70 78
74
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KRISHNAVENI 51 F 158
50 A I 7 T8 9 6 3 8 6.77 8.52 7.78 108
108 100 96 94 98 94 96 94 92 92 86 88 84 82 86 84 88 80 78 76 74 72 74 76 78 76 74
150
150 140 142 140 138 136 134 138 135 138 140 140 142 144 140 138 136 132 130 128 126 124 126 128 126 130 130 90 90 90 90 90 88 82 80 68 66 67 90 90 90 92 90 90 90 90 90 88 84 80 82 80
82
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PANDIAN 41 M 168
65 A II 20 T6 22 3 3 6 7.22 7.17 7.22 71
70 69 79 77 76 77 77 73 75 74 74 72 74 73 76 78 80 82 79 78 74 76 78 77 78 79 70
116
119 121 120 126 124 121 126 124 124 123 121 122 120 126 120 130 128 126 130 132 132 130 110 116 120 122 126 79 81 82 86 84 82 79 79 80 82 82 81 80 80 82 80 80 80 80 82 80 86 80 72 78
80
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A 0
RAJAGOPAL 60 M 160
60 A I 5 T4 8 3 3 6 4.72 5.22 6.75 63
63 62 60 57 56 52 50 52 55 56 55 53 40 60 62 64 66 68 70 72 74 72 70 68 72 70 72
133
133 123 128 126 124 120 124 116 116 114 110 116 110 122 120 122 120 120 116 130 128 130 130 130 128 126 120 91 91 90 83 77 76 82 76 78 74 72 70 72 70 86 80 82 80 80 80 80 80 90 80 90
82
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PANJAYAN 60 M 160
50 A I 2 T6 10 2 3 6 4.72 4.97 5.22 62
62 58 56 60 58 59 61 60 58 59 57 58 60 62 64 68 70 66 64 62 68 69 68 70 71 68 64
150
150 152 155 153 150 148 146 146 145 147 153 150 148 145 140 138 130 130 122 120 120 124 126 128 130 132 126 90 90 90 90 89 88 87 87 90 90 91 92 90 86 82 80 82 80 80 82 80 80 82 80 80
80
82 80
A 0
KARTHICK 28 M 158
60 A I 6 T6 12 2 3 10 6.15 6.9 7.22 68
68 56 55 58 54 52 49 53 50 57 56 55 54 58 60 68 70 68 72 70 72 68 70 74 72 70 68
138
138 136 130 128 130 128 129 125 123 117 115 114 112 120 120 124 122 126 130 132 130 128 125 126 128 127 126 88 88 84 82 84 84 82 84 82 83 83 83 82 84 83 80 82 84 81 82 80 80 82 86 82
80
84 80
A 0
MURUGANAND 55 M 160
60 A II 4 T6 5 2 3 7 4.18 4.93 5.22 82
81 66 70 70 67 64 62 60 62 61 66 56 58 60 64 68 72 74 70 80 82 84 86 84 82 80 80
142
141 108 106 106 104 103 100 101 102 104 102 103 100 116 112 114 120 124 126 128 130 128 126 124 122 126 124 78 79 76 74 74 73 72 70 72 70 68 68 71 72 74 76 74 72 78 74 78 76 74 75 70
75
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A S
SHANTHI 47 F 156
52 A II 6 T6 8 3 3 5 3.15 3.4 3.95 77
76 72 68 62 68 69 72 70 66 65 68 72 70 71 72 70 70 72 76 74 74 74 76 78 70 70 86
148
146 136 130 130 130 128 121 120 123 121 118 114 112 116 112 114 122 118 120 124 120 123 122 123 125 126 128 94 95 90 88 82 87 81 87 84 85 84 76 77 75 74 72 76 74 75 68 72 75 76 70 71
74
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A 0
VALLIAMMAL 40 F 150
56 A II 8 T4 10 3 3 7 6.67 7.47 6.33 78
76 68 66 69 67 65 62 65 60 61 62 70 72 76 73 71 70 70 75 72 72 72 74 70 73 70 65
125
124 115 116 123 120 121 116 114 118 121 120 121 120 126 130 128 124 121 125 126 126 122 126 120 128 122 126 80 80 78 78 72 76 78 76 74 76 72 76 74 76 74 78 76 72 74 74 76 72 74 72 72
74
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A 0
MOHANDAS 40 M 157
52 A I 2 T6 8 2 3 5 4.08 4.47 5.33 70
64 57 58 62 58 55 60 62 58 58 57 54 60 61 64 65 70 64 64 60 68 67 68 71 71 65 64
148
145 134 135 136 130 138 140 144 142 147 150 132 134 145 136 138 131 130 128 132 130 128 124 126 130 130 126 92 91 92 90 88 87 86 87 91 89 90 92 91 88 80 81 82 82 80 84 80 86 82 84 81
80
83 80
A 0
CHITTI BABU 54 M 158
60 A I 6 T6 10 3 3 8 6 6.67 6.87 68
67 57 55 59 64 52 50 52 55 56 56 54 54 57 62 68 71 66 73 70 70 68 70 75 72 71 68
134
138 130 130 128 130 125 129 120 123 118 115 111 112 114 120 120 122 124 130 128 130 126 125 126 127 127 128 82 87 84 84 84 83 82 80 82 80 81 82 84 86 83 88 80 82 81 80 80 81 82 84 82
85
84 83
A 0
SUBRAMANIAM 60 M 154
55 A II 15 T6 20 3 3 3 6.67 6.13 7 71
72 68 78 75 76 76 77 74 75 73 74 71 74 74 76 77 80 81 78 78 75 76 76 77 78 79 72
116
120 121 122 126 122 121 125 124 124 123 120 122 121 126 120 128 128 126 126 132 132 131 110 116 118 122 126 78 81 81 86 84 80 79 78 80 81 82 80 80 86 82 82 80 80 81 82 84 86 81 72 76
80
80 82
A S
VELU 64 M 156
57 A I 6 T6 10 2 3 5 6 7.5 6.67 69
70 54 54 56 54 52 48 53 52 57 55 55 50 58 61 68 72 68 70 70 71 68 78 74 70 70 67
138
132 136 131 128 126 128 127 125 120 117 114 114 110 120 118 124 120 126 128 132 131 128 124 126 127 127 125 88 87 82 82 86 84 85 84 80 83 82 83 80 84 82 80 89 84 80 82 81 80 83 86 86
80
87 80
A 0
MAHABOOBI 33 F 160
62 A II 18 T6 20 2 3 5 7.53 7.8 7 71
71 68 76 68 69 78 76 72 74 72 74 70 72 71 75 77 81 80 78 77 76 75 77 78 79 80 81
115
118 120 118 126 122 121 126 124 125 123 121 123 120 126 122 130 126 126 128 130 131 128 114 114 119 120 126 78 80 81 85 83 84 78 76 81 80 81 80 86 82 83 84 85 88 81 83 82 86 86 72 76
80
81 82
A 0
SIVAKUMAR 46 M 156
60 A II 5 T6 10 5 3 16 5 5.17 4.67 85
86 86 88 89 90 92 88 76 71 72 68 71 71 72 67 64 70 74 71 70 70 72 72 75 80 82 74
138
130 135 136 130 140 130 132 135 131 128 133 129 131 130 120 123 101 122 123 122 125 127 128 120 118 120 124 98 91 96 102 100 100 101 92 89 90 92 93 90 91 92 82 86 68 82 80 82 82 82 87 82
78
80 88
A 0
RAMAN 54 M 158
60 A I 7 T6 8 5 3 6 4.3 5.97 5.17 72
70 68 65 66 60 62 64 59 60 72 82 88 85 90 88 86 87 82 78 76 74 72 76 78 77 78 76
128
125 126 130 126 125 120 121 118 119 120 114 116 118 120 122 126 122 126 120 118 118 120 120 124 124 124 120 88 86 80 78 70 68 78 70 68 68 70 76 80 82 82 84 84 80 78 72 74 76 82 81 84
86
82 78
A 0
SRIKAR 24 M 154
59 A I 10 T6 15 5 3 8 3.17 4.17 5 78
74 70 68 68 66 68 70 72 70 72 68 68 70 71 70 72 74 74 76 72 74 72 78 72 70 71 80
136
130 128 126 124 122 120 120 118 122 121 118 116 112 116 112 114 118 118 120 124 122 121 120 124 125 124 126 88 90 88 86 84 82 80 84 86 88 90 78 76 76 74 70 76 72 72 74 70 72 76 72 78
76
78 78
A 0
KARTHIKEYAN 19 M 156
50 A I 7 T6 8 3 3 8 3 3.5 4 76
74 70 68 68 70 70 72 72 68 68 70 72 72 70 72 74 72 70 76 74 78 74 76 76 72 72 80
128
126 126 120 120 120 118 120 118 120 122 118 116 120 118 116 116 120 118 122 124 122 124 120 122 124 124 126 88 90 88 86 80 86 80 86 84 86 84 78 78 74 76 78 76 72 74 70 68 74 72 72 74
72
76 74
A 0
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